SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2023 Biotech Charity Contest
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: technetium who wrote (93)5/3/2023 1:20:04 PM
From: Arthur Radley  Read Replies (2) of 233
 
My two “eye” portfolio stocks have shown stellar performances (EYEN) and (ISEE). Luckily I own both stocks in my personal stock account with a major overweight in Eyenova. They have a FDA decision happening next Tuesday.( ISEE )has nearly double YTD and this is because they are being purchased by Astellas(ALPMY) for $5.9 billion, or $40.00 per share. The deal is scheduled to be closed in the 3rd Q. For those who like short term profits with a spread for this buyout ($37.50 vs $40.00) this $2.50 is a nice profit.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News